Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives
Uloženo v:
| Název: | Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives |
|---|---|
| Autoři: | Jörg Trojan |
| Zdroj: | Drugs |
| Informace o vydavateli: | Springer Science and Business Media LLC, 2020. |
| Rok vydání: | 2020 |
| Témata: | 0301 basic medicine, ddc:610, Clinical Trials as Topic, Carcinoma, Hepatocellular, Pyridines, Liver Neoplasms, Antineoplastic Agents, Review Article, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Humans, Anilides/therapeutic use [MeSH], Pharmacology/Toxicology, Antineoplastic Agents/adverse effects [MeSH], Pyridines/therapeutic use [MeSH], Humans [MeSH], Pyridines/adverse effects [MeSH], Carcinoma, Hepatocellular/drug therapy [MeSH], Anilides/adverse effects [MeSH], Clinical Trials as Topic [MeSH], Antineoplastic Agents/therapeutic use [MeSH], Internal Medicine, Liver Neoplasms/drug therapy [MeSH], Pharmacotherapy, Anilides |
| Popis: | Cabozantinib (Cabometyx®) is a potent multikinase inhibitor targeting the vascular endothelial growth factor (VEGF) receptor 2, the mesenchymal-epithelial transition factor (MET) receptor, and the "anexelekto" (AXL) receptor tyrosine kinase. It is approved for the treatment of advanced hepatocellular carcinoma (HCC) after failure of sorafenib in Europe (since November 2018) and in the USA (since January 2019). The approval of cabozantinib was based on results of the randomized, placebo-controlled, phase 3 CELESTIAL trial in patients with unresectable HCC, who received one or two prior lines of treatment including sorafenib. At the second planned interim analysis, the trial was stopped, because the primary end point overall survival was clearly in favor for cabozantinib. Additionally, median progression-free survival was superior to placebo. The most common ≥ grade 3 relevant adverse events in patients with HCC treated with cabozantinib were palmar-plantar erythrodysesthesia, hypertension, fatigue, and diarrhea. In this review, current data on cabozantinib for the treatment of patients with advanced HCC, with a focus on the management of common adverse events and ongoing clinical trials, are discussed. |
| Druh dokumentu: | Article Other literature type |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1179-1950 0012-6667 |
| DOI: | 10.1007/s40265-020-01361-5 |
| Přístupová URL adresa: | https://link.springer.com/content/pdf/10.1007/s40265-020-01361-5.pdf https://pubmed.ncbi.nlm.nih.gov/32671719 https://pubmed.ncbi.nlm.nih.gov/32671719/ https://link.springer.com/content/pdf/10.1007/s40265-020-01361-5.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395054/ https://www.ncbi.nlm.nih.gov/pubmed/32671719 https://link.springer.com/article/10.1007/s40265-020-01361-5 https://repository.publisso.de/resource/frl:6465121 |
| Rights: | CC BY NC |
| Přístupové číslo: | edsair.doi.dedup.....3be27b01cd1ceafe3120d4de5e1a038d |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Cabozantinib (Cabometyx®) is a potent multikinase inhibitor targeting the vascular endothelial growth factor (VEGF) receptor 2, the mesenchymal-epithelial transition factor (MET) receptor, and the "anexelekto" (AXL) receptor tyrosine kinase. It is approved for the treatment of advanced hepatocellular carcinoma (HCC) after failure of sorafenib in Europe (since November 2018) and in the USA (since January 2019). The approval of cabozantinib was based on results of the randomized, placebo-controlled, phase 3 CELESTIAL trial in patients with unresectable HCC, who received one or two prior lines of treatment including sorafenib. At the second planned interim analysis, the trial was stopped, because the primary end point overall survival was clearly in favor for cabozantinib. Additionally, median progression-free survival was superior to placebo. The most common ≥ grade 3 relevant adverse events in patients with HCC treated with cabozantinib were palmar-plantar erythrodysesthesia, hypertension, fatigue, and diarrhea. In this review, current data on cabozantinib for the treatment of patients with advanced HCC, with a focus on the management of common adverse events and ongoing clinical trials, are discussed. |
|---|---|
| ISSN: | 11791950 00126667 |
| DOI: | 10.1007/s40265-020-01361-5 |